Stock Notes

Concord Biotech

Every Finvezto stock note on Concord Biotech, dated and newest first. Coverage spans pharma.

1 note and counting
10 Jun 2026
Concord Biotech received USFDA approval for its tofacitinib tablets in 5 mg and 10 mg strengths, addressing a US market worth about 500 million dollars.
The arthritis and ulcerative-colitis drug marks Concord's push from fermentation-based APIs into finished formulations, a higher-margin segment that lifted its shares 6 percent on the news.
Finvezto Membership

Get the research behind the notes

Stock notes are the free daily layer. The membership carries the full Flexi-Wealth system: an ETF core portfolio with monthly rebalancing signals, fifteen quality-momentum stocks with exact weightages every month, options income and hedging recommendations, and the institutional data toolkit. One flat membership covers everything.

Become a Member Read free sample research →

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630. Stock notes are market commentary for general information and education. They are not investment advice, not a recommendation to buy or sell, and do not account for any individual's financial situation. Investment in securities is subject to market risks. Please read all related documents carefully before investing. Past performance is not a guarantee of future results.